Development of a novel celecoxib-loaded nanosuspension using a wet media milling process
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Sung Chan | - |
dc.contributor.author | Kim, Dong Shik | - |
dc.contributor.author | Jin, Sung Giu | - |
dc.contributor.author | Youn, Yu Seok | - |
dc.contributor.author | Oh, Kyung Taek | - |
dc.contributor.author | Li, Dong Xun | - |
dc.contributor.author | Yong, Chul Soon | - |
dc.contributor.author | Kim, Jong Oh | - |
dc.contributor.author | Kim, Kyeong Soo | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.date.available | 2019-05-28T03:38:54Z | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 0031-7144 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/18685 | - |
dc.description.abstract | To develop a novel celecoxib (CXB)-loaded drug delivery system, numerous nanosuspensions were prepared with various polymers and surfactants using a wet media milling process, and their particle sizes were subsequently determined. A 2(4) full factorial design was used to identify the most appropriate preparation conditions. Pharmacokinetics of the selected nanosuspension were performed in rats and compared with those of a drug powder and a commercial CXB-loaded product. Among the carriers investigated, copovidone and sodium lauryl sulphate gave the smallest particle size of the drug in the nanosuspension. In particular, the nanosuspension prepared with 5% CXB, 4% copovidone, and 0.1% sodium lauryl sulphate, under the appropriate conditions, showed a particle size of approximately 190 nm, which was physically stable for at least 8 weeks. This nanosuspension provided a significantly higher plasma concentration and AUC in rats as compared with the drug powder and the commercial product. Thus, this novel CXB-loaded nanosuspension is a promising candidate with excellent stability and enhanced oral bioavailability. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | GOVI-VERLAG PHARMAZEUTISCHER VERLAG GMBH | - |
dc.title | Development of a novel celecoxib-loaded nanosuspension using a wet media milling process | - |
dc.type | Article | - |
dc.identifier.doi | 10.1691/ph.2018.8035 | - |
dc.identifier.bibliographicCitation | PHARMAZIE, v.73, no.9, pp 498 - 502 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000455317000003 | - |
dc.identifier.scopusid | 2-s2.0-85053699895 | - |
dc.citation.endPage | 502 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 498 | - |
dc.citation.title | PHARMAZIE | - |
dc.citation.volume | 73 | - |
dc.type.docType | Article | - |
dc.publisher.location | 독일 | - |
dc.subject.keywordPlus | PHYSICOCHEMICAL CHARACTERIZATION | - |
dc.subject.keywordPlus | SOLUBILITY ENHANCEMENT | - |
dc.subject.keywordPlus | ORAL BIOAVAILABILITY | - |
dc.subject.keywordPlus | DISSOLUTION BEHAVIOR | - |
dc.subject.keywordPlus | TWEEN 80 | - |
dc.subject.keywordPlus | FORMULATION | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | OPTIMIZATION | - |
dc.subject.keywordPlus | PERFORMANCE | - |
dc.subject.keywordPlus | ABSORPTION | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.